Cardiovascular Effects of Chemo-Radiation in Hodgkin's Lymphoma Analyzed

Share this content:
Certain doses of radiation and anthracycline therapy for the treatment of Hodgkin’s lymphoma may increase the risk of cardiovascular events.
Certain doses of radiation and anthracycline therapy for the treatment of Hodgkin’s lymphoma may increase the risk of cardiovascular events.

Certain doses of radiation and anthracycline therapy for the treatment of Hodgkin's lymphoma may increase the risk of cardiovascular events, according to a retrospective analysis published in Lancet Haematology.1

A Life Situation Questionnaire (LSQ) was mailed to patients who were enrolled in the European Organisation for Research and Treatment of Cancer (EORTC) and Groupe d'Etude des Lymphomes de l'Adulte (GELA or LYSA) trials from 1964 to 2004.

Of the 6,039 patients whose information on primary treatment was obtained, 1,919 responded to the LSQ. In 703 patients, 1,238 first cardiovascular events were recorded: ischemic heart disease (19%), congestive heart failure (12%), arrhythmia (16%), and valvular disease (11%).

Cumulative doses of vinblastine (P=.77) and vincristine (P=.36), and mean radiation dose to the left (P=.41) or right (P=.70) internal carotid artery did not serve as predictors for cardiovascular events.

RELATED: Genetic Variants, Treatment Response in B-Cell Lymphoma Investigated

The mean heart radiation dose per 1 Gy increase (hazard ratio [HR] 1.015; 95% CI, 1.006-1.024; P=.0014), and the dose of anthracyclines per 50 mg/m2 increase in cumulative dose (HR, 1.077; 95% CI, 1.021-1.137; P=.0064) significantly impacted the risk of cardiovascular disease development.

Investigators concluded that quantification of cardiovascular risk with specific doses of chemo-radiation will allow for health care providers to further individualize regimens for patients.

Reference

  1. Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials [published online ahead of print October 14, 2015] Lancet. doi: 10.106/S2532-3026(15)00153-2.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters